Advanced Pharmaceutical Bulletin (Mar 2022)

Exendin-4 as a Versatile Therapeutic Agent for the Amelioration of Diabetic Changes

  • Hadi Rajabi,
  • Mahdi Ahmadi,
  • Somayeh Aslani,
  • Shirin Saberianpour,
  • Reza Rahbarghazi

DOI
https://doi.org/10.34172/apb.2022.025
Journal volume & issue
Vol. 12, no. 2
pp. 237 – 247

Abstract

Read online

Type 2 diabetes mellitus (T2DM) is a chronic metabolic abnormality leading to microvascular and macrovascular complications. Non-insulin Incretin mimic synthetic peptide exendin-4 was introduced as an anti-diabetic drug which helped diabetic patients with triggering insulin secretion; further researches have revealed an effective role of exendin-4 in treatment of T2DM related diseases. Exendin-4 is approximately similar to Glucagon-like peptide, thus it can bind to the glucagon-like peptide-1 receptor (GLP-1R) and activated different signaling pathways that are involved in various bioactivities such as apoptosis, insulin secretion and inactivation of microglial. In this review, we investigated the interesting role of exendin-4 in various kinds of T2DM related disorders through the activation of different signaling pathways.

Keywords